It has been discovered that interactions between DCs and MM cells can confer proliferation, survival, and medication resistance against tumor cells through receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) signaling and a proliferation-inducing ligand (APRIL)-mediated interactions (21), as well as CD28 and CD80/CD86 crosslinking (22, 23). This evidence concerns the gene TNFSF13 and Miyoshi myopathy.